Stock Report: Endocyte Inc. (ECYT) Report Updated: May 13, 2013 | Print This Page

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company’s principal SMDC product candidate, EC145, has been evaluated in a randomized Phase II clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a Phase II single-arm clinical trial for pre-treated non-small cell lung cancer. Its preclinical development products include EC0489 and EC0225, which are in Phase I clinical trial for the treatment of solid cancer tumors; EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC0531, a tubulysin conjugate to treat solid tumors; and EC0746 and EC0565 foliate receptors for the reduction of inflammation. The company’s products under development also comprise EC20, a proprietary companion imaging diagnostic product for the identification of folate receptor in cancer patients; EC1069 for prostate cancer therapy; and EC0652 that is in early clinical trials for use as a companion imaging diagnostic for SMDCs. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.